• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down Over 100 Points; US Trade Deficit Shrinks In June

    8/8/23 9:50:58 AM ET
    $BURU
    $DRUG
    $DTSS
    $PTRA
    Industrial Machinery/Components
    Miscellaneous
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BURU alert in real time by email

    U.S. stocks were lower this morning, with the Nasdaq Composite falling more than 100 points on Tuesday.

    Following the market opening Tuesday, the Dow traded down 0.82% to 35,182.19 while the NASDAQ fell 0.81% to 13,880.85. The S&P 500, also fell, dropping, 0.72% to 4,486.06.

    Check This Out: Top 5 Tech Stocks Which Could Rescue Your Portfolio This Month

     

    Leading and Lagging Sectors

    • Health care shares jumped by 0.7% on Tuesday.
    • In trading on Tuesday, energy shares fell 2%.

     

    Top Headline

    The U.S. trade deficit shrank to a three-month low level of $65.5 billion in June versus a revised $68.3 billion in May.

    Exports from the U.S. fell by $0.3 billion to $247.5 billion in June, while imports fell by $3.1 billion to $313.0 billion.

     

    Equities Trading UP

    • Nuburu, Inc. (NYSE:BURU) shares shot up 215% to $1.83 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser technology.
    • Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) got a boost, shooting 74% to $0.4539 after falling more than 10% on Monday.
    • Bright Minds Biosciences Inc. (NASDAQ:DRUG) shares were also up, gaining 95% to $6.33 after the company disclosed data for BMB-101.

     

    Equities Trading DOWN

    • Proterra Inc. (NASDAQ:PTRA) shares dropped 76% to $0.3470 after the company announced it filed for Chapter 11 bankruptcy.
    • Shares of SeaChange International, Inc. (NASDAQ:SEAC) were down 38% to $4.9047 after the company announced voluntary SEC deregistration and Nasdaq delisting.
    • Datasea Inc. (NASDAQ:DTSS) was down, falling 32% to $0.77. Datasea said on August 1 that it entered into two separate subscription agreements with a certain non-U.S. investor to sell an aggregate of 4.8 million shares of common stock at $1.20 per share.

    Also Check This Out: McKesson, Kinder Morgan And 2 Other Stocks Insiders Are Selling

     

    Commodities

    In commodity news, oil traded down 1.3% to $80.85 while gold traded down 0.4% at $1,961.80.

    Silver traded down 1.4% to $22.91 on Tuesday while copper fell 2% to $3.7595.

     

    Euro zone

    European shares were lower today. The eurozone’s STOXX 600 fell 0.6%, London’s FTSE 100 fell 0.7% while Spain’s IBEX 35 Index fell 1.1% The German DAX declined 1.4% French CAC 40 fell 1.1% and Italy’s FTSE MIB Index declined 2.4%.

    French trade deficit shrank to EUR 6.7 billion in June, recording the lowest level since Aug. 2021, while the country posted a current account surplus of EUR 0.8 billion in June compared to a EUR 0.7 billion deficit in the prior month. The annual inflation rate in Germany fell to 6.2% in July from 6.4% in June. Retail sales in the UK increased 1.8% year-over-year in July.

     

    Asia Pacific Markets

    Asian markets closed mostly lower on Tuesday, with Japan’s Nikkei 225 rising 0.38%, China’s Shanghai Composite Index falling 0.25% and Hong Kong’s Hang Seng Index declining 1.81%. India’s S&P BSE Sensex, meanwhile, fell 0.1%.

    The gauge for Japan's service sector sentiment rose to 54.4 in July from 53.6 in the earlier month, while average cash earnings in the country rose by 2.3% year-over-year in June. Japan's current account surplus widened to JPY 1,508.8 billion in June compared to JPY 497.9 billion in the year-ago month. Chinese trade surplus shrank to $80.6 billion in July from $102.7 billion in the year-ago period.

    Australia's NAB business confidence index rose to 2 in July versus a revised reading of -1 in the previous month, while the Westpac-Melbourne Institute Consumer Sentiment index declined by 0.4% month-over-month to a reading of 81.0 in August.

     

    Economics

    • The NFIB Small Business Optimism Index rose for a third straight month to a reading of 91.9 in July.
    • The U.S. trade deficit shrank to a three-month low level of $65.5 billion in June versus a revised $68.3 billion in May.
    • Exports from the U.S. fell by $0.3 billion to $247.5 billion in June, while imports fell by $3.1 billion to $313.0 billion.

    Now Read This: DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,566,780 cases with around 1,170,780 deaths. India confirmed a total of at least 44,996,030 cases and 531,910 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 692,993,500 cases of COVID-19 worldwide with more than 6,905,480 deaths.

    Get the next $BURU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BURU
    $DRUG
    $DTSS
    $PTRA

    CompanyDatePrice TargetRatingAnalyst
    Bright Minds Biosciences Inc.
    $DRUG
    9/8/2025$72.00Buy
    BTIG Research
    Bright Minds Biosciences Inc.
    $DRUG
    5/13/2025Buy
    TD Cowen
    Bright Minds Biosciences Inc.
    $DRUG
    5/7/2025$80.00Buy
    Chardan Capital Markets
    Bright Minds Biosciences Inc.
    $DRUG
    1/23/2025$93.00Overweight
    Piper Sandler
    Bright Minds Biosciences Inc.
    $DRUG
    1/10/2025Overweight
    Cantor Fitzgerald
    Bright Minds Biosciences Inc.
    $DRUG
    1/10/2025$85.00Buy
    H.C. Wainwright
    Bright Minds Biosciences Inc.
    $DRUG
    11/26/2024$75.00Outperform
    Robert W. Baird
    Proterra Inc.
    $PTRA
    8/8/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $BURU
    $DRUG
    $DTSS
    $PTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Bright Minds Biosciences with a new price target

    BTIG Research initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $72.00

    9/8/25 8:48:58 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Bright Minds Biosciences

    TD Cowen initiated coverage of Bright Minds Biosciences with a rating of Buy

    5/13/25 9:38:46 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Bright Minds Biosciences with a new price target

    Chardan Capital Markets initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $80.00

    5/7/25 8:37:12 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BURU
    $DRUG
    $DTSS
    $PTRA
    SEC Filings

    View All

    Vivos Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    2/6/26 4:05:34 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.

    SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

    2/6/26 3:00:09 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Nuburu Inc.

    PRE 14A - Nuburu, Inc. (0001814215) (Filer)

    2/3/26 5:16:20 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    $BURU
    $DRUG
    $DTSS
    $PTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 5 filed by Barisoni Dario

    5 - Nuburu, Inc. (0001814215) (Issuer)

    2/5/26 6:14:50 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 3 filed by new insider Barisoni Dario

    3 - Nuburu, Inc. (0001814215) (Issuer)

    2/5/26 6:12:27 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 5 filed by Taylor Shawn

    5 - Nuburu, Inc. (0001814215) (Issuer)

    2/5/26 5:45:08 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    $BURU
    $DRUG
    $DTSS
    $PTRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

    4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

    11/6/24 4:20:48 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

    4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

    10/17/24 5:11:29 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BURU
    $DRUG
    $DTSS
    $PTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

    Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration to advance public awareness and access to SoundHealth's consumer-focused airway and sleep health technologies. The collaboration leverages Vivos' extensive national network of over 2,00

    2/5/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    NUBURU Accelerates Defense & Security Platform Execution While Advancing Balance Sheet Transformation and Multi-Vertical Technology Integration

    Company Progresses Tekne Industrial Cooperation, Laser-Driven Directed-Energy Initiatives, Software Orchestration Expansion, and Advanced Manufacturing Strategy NUBURU, Inc. (NYSE:BURU), a developer of high-performance blue-laser technology and an emerging integrated Defense & Security platform provider, today provided a corporate update highlighting continued execution of its strategic transformation, including balance-sheet optimization initiatives, expansion of defense-focused industrial cooperation, and advancement across multiple technology verticals. Strategic Transformation Moving into Multi-Vertical Execution Phase Over the past year, NUBURU has transitioned from a single-tech

    2/5/26 7:20:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    NUBURU Strengthens Defense & Security Capabilities with Control of Orbit's SaaS Operational Resilience Platform

    Orbit consolidation adds a recurring-revenue Software-as-Service business model as NUBURU advances toward its dual-use strategy through the integration of laser systems, drone platforms, and electronic-warfare technologies. NUBURU, Inc. (NYSE:BURU), a global pioneer in high-performance blue laser technology, today announced that it has secured operating control of Orbit S.r.l. ("Orbit"), a revenue-generating Software-as-a-Service ("SaaS") company focused on operational resilience, risk intelligence, and mission-critical decision support. The transaction strengthens NUBURU's security offering capabilities and advances the Company's multi-vertical growth strategy through the addition of a s

    1/22/26 7:05:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    $BURU
    $DRUG
    $DTSS
    $PTRA
    Leadership Updates

    Live Leadership Updates

    View All

    NUBURU Strengthens Balance Sheet, Advances Defense-Tech Acquisition Program and Revamps Blue-Laser Business

    Executing Transformation Plan spanning Maddox Defense drones, Tekne special-mission vehicles, and Orbit critical-infrastructure software to build a unified defense-tech platform with expanding NATO traction. Blue-laser technology' business acquisition on track. NUBURU, Inc. (NYSE:BURU) ("NUBURU" or the "Company") continued strengthening its balance sheet during the quarter through disciplined capital deployment, selective drawdowns under its Standby Equity Purchase Agreement when beneficial, and further reduction of legacy payables. Cash on hand remains robust as NUBURU strategically allocates capital to high-value defense and security growth initiatives under its Transformation Plan. "We

    11/6/25 7:30:00 AM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

    LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e

    7/30/25 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

    -- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an

    1/7/25 6:50:00 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BURU
    $DRUG
    $DTSS
    $PTRA
    Financials

    Live finance-specific insights

    View All

    Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

    BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no change in total sleep durationCompany has initiated preparations for global registrational trials in both DEE and Absence Seizure patientsBright Minds to hold conference call and live webcast at 8AM ET today NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical

    1/6/26 7:16:55 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

    – Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. Webcast Information The Bright Minds virtual event will be webcast live and a replay will be available after th

    1/5/26 4:30:00 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

    Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), t

    11/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $BURU
    $DRUG
    $DTSS
    $PTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nuburu Inc.

    SC 13D/A - Nuburu, Inc. (0001814215) (Subject)

    11/25/24 8:59:19 PM ET
    $BURU
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:49:30 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:05:24 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care